Aura Biosciences, Inc.
Tremor tracks 3 of its cancer trials.
Company-wide warning signs
These add points to every one of this company's trials.
- Announced layoffs or restructuringSince Aug 11, 2026+5.5
Trials
- AURAAura Biosciences16Calm
Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma
FinishedPhase 222 patientsMain results: Apr 22, 2024 - AURAAura Biosciences6Calm
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
Running, no new patientsPhase 3108 patientsMain results: Nov 15, 2027 - AURAAura Biosciences6Calm
Suprachoroidal Administration in Subjects With Metastases to the Choroid
Signing up patientsPhase 224 patientsMain results: Nov 30, 2026
Key executives leaving
From the last 12 months of the company's SEC reports.
Insider trades (last 6 months)
“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.
1 sale (1 not pre-planned) · 0 purchases
- Gibney Anthony SSee Remarks · Jun 16, 2026Sold 12,824 sharesabout $82 thousand · not pre-planned
Recent SEC filings
Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.
- Quarterly reportQuarterly report (10-Q)Nov 9, 2026
- Shared quarterly results; Other newsNews report (8-K)Nov 9, 2026
- Permission to sell new sharesPermission to sell new shares (S-3)Aug 11, 2026
- Quarterly reportQuarterly report (10-Q)Aug 11, 2026
- Shared quarterly results; Layoffs or restructuring costs; An executive or board member joined or left; Other newsNews report (8-K)Aug 11, 2026